Patients react after failure of promising Alzheimer drug trial: ‘Like the rug was pulled out from under us’

| | April 10, 2019
4-4-2019 image x
Patient Debby Rosenkrantz (left) and her wife Susan Woskie, with a friend’s newborn. Image: Debbie Rosenkrantz/STAT
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

When Biogen and its partner Eisai announced that they were stopping two phase 3 trials of the Alzheimer’s treatment aducanumab because the drug did not appear to be working, it shattered the faith that a truly effective therapy — one that could decelerate the descent that came with the disease — was finally in reach. It ignited reckonings both for Massachusetts-based Biogen and for the underlying scientific theory of Alzheimer’s on which aducanumab was constructed.

But as broadly as the disappointment was felt, the blow to the roughly 3,200 people in the trials and their families was particularly acute. The news … came with the realizations that the drug hadn’t been staving off their neurodegenerative decline.

Related article:  How your history with the flu could shape your body's response to vaccines

“Like the rug was pulled out from under us.”

“I felt defeated because I went on the Internet and looked around and there’s just nothing else.”

“I had this overwhelming sense of dread, almost like a hopelessness.”

Talking to families that day, said Kris Kauno, the clinical trials supervisor at the University of Washington’s Alzheimer’s Disease Research Center, “was one of the hardest things I have ever had to do.”

Read full, original post: When the ‘real thing’ becomes a mirage: How patients in Alzheimer’s trials are coping with the treatment’s failure

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend